Inhibikase Therapeutics Q3 2024 GAAP EPS $(0.65) Misses $(0.37) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.37) by 75.68 percent.
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.37) by 75.68 percent.